Effect of cigarette smoking on CYP2C9 activity.

被引：2
|
作者：
Kim, M
LaCourse, J
Nafziger, AN
Wallace, AL
Kashuba, AD
Rowland, E
Gaedigk, A
Bertino, JS
机构：
[1] Bassett Healthcare, Cooperstown, NY USA
[2] Univ N Carolina, Chapel Hill, NC 27515 USA
[3] Childrens Mercy Hosp, Cooperstown, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90407-3
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P14 / P14
页数：1
相关论文
共 50 条
  • [1] Flurbiprofen as a selective in vivo probe of CYP2C9 activity.
    Frye, RF
    Tracy, TS
    Hutzler, JM
    Korzekwa, KR
    Cannon, Y
    Pauli, M
    Huang, SM
    Branch, RA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 109 - 109
  • [2] Phenytoin metabolic ratio: A putative probe of CYP2C9 activity.
    Caraco, Y
    Muszkat, M
    Wood, AJJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 98 - 98
  • [3] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Satoshi Yamaori
    Mika Kushihara
    Kyoko Koeda
    Ikuo Yamamoto
    Kazuhito Watanabe
    Forensic Toxicology, 2013, 31 : 70 - 75
  • [4] Significance of CYP2C9 genetic polymorphism in inhibitory effect of Δ9-tetrahydrocannabinol on CYP2C9 activity
    Yamaori, Satoshi
    Kushihara, Mika
    Koeda, Kyoko
    Yamamoto, Ikuo
    Watanabe, Kazuhito
    FORENSIC TOXICOLOGY, 2013, 31 (01) : 70 - 75
  • [5] Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Myong-Jin Kim
    Anne N. Nafziger
    Angela D. M. Kashuba
    Julia Kirchheiner
    Steffen Bauer
    Andrea Gaedigk
    Joseph S. Bertino
    European Journal of Clinical Pharmacology, 2006, 62 : 431 - 436
  • [6] Effects of fluvastatin and cigarette smoking on CYP2C9 activity measured using the probe S-warfarin
    Kim, Myong-Jin
    Nafziger, Anne N.
    Kashuba, Angela D. M.
    Kirchheiner, Julia
    Bauer, Steffen
    Gaedigk, Andrea
    Bertino, Joseph S., Jr.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 431 - 436
  • [7] Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype
    Dericioglu, N
    Babaoglu, MO
    Saygi, S
    Bozkurt, A
    Yasar, U
    ANNALS OF PHARMACOTHERAPY, 2004, 38 (05) : 899 - 899
  • [8] Metabolism of dapsone by CYP2C9 and its effect on CYP2C9 substrates.
    Tracy, TS
    Metz, CA
    Korzekwa, KR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 152 - 152
  • [9] Endstage renal disease (ESRD) reduces hepatic cytochrome P450CYP2C9 (CYP2C9) activity.
    Dreisbach, AW
    Japa, S
    Kamath, BL
    Mowry, SE
    Gebrekal, AB
    Lertora, JJL
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 716A - 716A
  • [10] CYP2C9 polymorphisms and CYP2C9*2 genotyping primers
    Goldstein, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 53 (04) : 409 - 410
12345